Last updated: April 26, 2026
What is vorasidenib and where is it approved?
Vorasidenib (Voranigo; IDH1/2 inhibitor) is an orally administered, targeted therapy for advanced IDH-mutant glioma. The commercial label (US) is tied to molecularly defined disease and clinician selection based on IDH mutation status and line of therapy.
Key development and regulatory milestones (selected)
- Phase 3 (INDIGO): Demonstrated progression-free survival and overall survival outcomes versus placebo in IDH1/2-mutant low-grade glioma after surgery (primary endpoint structure depends on interim vs final readouts).
- Phase 3 (AGILE): Ongoing/expanded program for broader IDH-mutant settings across tumor types (program structure varies by cohort).
- US approval: Granted based on IDH-mutant low-grade glioma data from INDIGO.
- Label expansion: Conducts through additional readouts as the program matures (post-approval updates track to new endpoints and earlier-line adoption).
Commercial entity
- Company: Servier and partner entities (commercialization with regional responsibility differs by geography).
What do the pivotal clinical datasets show?
INDIGO (phase 3) for IDH-mutant low-grade glioma
INDIGO is the anchor study underpinning vorasidenib’s label. Core takeaways are consistent across public disclosures: the drug improves disease control vs placebo in IDH-mutant low-grade glioma after surgery.
Published trial outcomes (pivotal)
- Progression-free survival (PFS): Improved vs placebo (statistically significant).
- Overall survival (OS): Updated analyses reported subsequent to initial PFS success, with longer-term readouts continuing to drive adoption narratives in oncology market access discussions.
- Subgroup durability: Benefit persists across IDH1/IDH2-mutant categories and extent-of-resection strata in public reporting.
(INDIGO is the trial investors and payers cite for durability and sequencing positioning.)
AGILE (phase 2) and combination/expansion cohorts
AGILE is the platform-style program capturing efficacy signals in additional IDH-mutant oncology settings. Public updates consistently emphasize response rates, depth of response, and tolerability across cohorts, with ongoing maturation as longer follow-up accrues.
Why this matters for commercial trajectory
- Low-grade glioma is a long-duration market with low patient counts but high value per patient.
- Earlier line placement depends on evidence for CNS activity, tolerability allowing chronic dosing, and sequencing relative to chemotherapy and radiation.
How is the clinical development pipeline progressing (what is likely to move adoption)?
The near-term market mover for vorasidenib is additional clinical readouts that reduce uncertainty on OS and durability and clarify best-use positioning (post-surgery, extent of resection, and IDH mutation split). The other mover is phase 2/3 expansions that widen the eligible population or create combination regimens that improve response durability.
Pipeline structure (market-relevant)
- Phase 3 disease-basket maturation: Continued follow-up in the INDIGO framework to firm up OS.
- Earlier intervention narratives: Evidence that supports using vorasidenib sooner than current standard of care for surgically treated IDH-mutant low-grade glioma.
- IDH1 vs IDH2 differentiation: Data that tightens payer and prescriber confidence in consistent efficacy across mutation types.
Adoption bottleneck
- CNS oncology requires strong tolerability and meaningful time-to-progression endpoints since patients can live long enough for long-term safety and quality of life to become deciding factors.
What is the competitive landscape?
Vorasidenib competes in IDH-mutant glioma and, more broadly, targets IDH biology across oncology. The competitive set is defined by:
- Direct IDH inhibition (IDH1 and IDH2 inhibitors used for tumor biology and possibly used off-label depending on evidence)
- Non-IDH targeted strategies (standard chemo-radiation approaches where IDH therapy is used for molecularly selected patients)
- Sequencing with surgery and radiation: In low-grade glioma, clinical practice hinges on resection extent and timing of radiation.
Commercial implication
- Adoption depends less on marginal response metrics and more on durability, chronic dosing feasibility, and payer comfort with biomarker-driven selection.
What is the treatable addressable population?
Vorasidenib targets a relatively small but high-value population: IDH-mutant low-grade glioma (and potentially expanded IDH-mutant CNS indications depending on evidence and label). Addressable volume is constrained by:
- Prevalence of IDH1/IDH2 mutations
- Eligibility after surgery
- Practice patterns for upfront vs delayed systemic therapy
- Biomarker testing penetration in real-world settings
Commercially relevant segmentation
- New diagnosis post-resection patients who are “watch-and-wait” candidates prior to radiation
- Patients who progress and require systemic therapy
- Biomarker-screened patients where IDH mutation confirmation is routine
What is the current market structure (value drivers)?
Key value drivers
- Time on therapy: Chronic oral dosing typically supports high net revenue per patient when disease control is durable.
- Line of therapy: Earlier use drives volume; later use limits volume but may be higher in price-throughput if only a subset progresses.
- Payer criteria: Biomarker confirmation and prior therapy requirements determine access velocity.
- Provider confidence: CNS-specific efficacy and safety tolerability affects switching.
How do pricing and reimbursement shape projections?
Vorasidenib’s revenue profile is driven by launch dynamics and subsequent contract negotiations:
- US commercial revenue is constrained by payer formulary decisions, step edits, and prior authorization.
- Europe and other regions show slower adoption where reimbursement timelines extend, especially for CNS oncology where value assessments are strict.
Market access priorities
- Documentation of IDH mutation status
- Evidence tied to specific lines (post-surgery, before radiation in relevant label scenarios)
- Health economic evaluation built around delayed progression rather than response rate alone
Market analysis and projections (2026-2032)
Base-case commercial adoption model
The following model framework translates clinical uptake into revenue:
- Patient pool build: diagnosis rate times IDH mutation prevalence times testing penetration
- Share capture: displacement from “surveillance, chemo, radiation timing” to oral IDH therapy
- Switching curve: ramp post-label stabilization and after OS/durability readouts reduce payer friction
- Treatment duration: based on PFS curves and progression rate
Revenue projection ranges
All figures are scenario-based and designed for decision use, not GAAP reporting.
US revenue (base case)
- 2026: $0.9B to $1.6B
- 2028: $1.5B to $2.9B
- 2032: $2.6B to $4.4B
Global revenue (base case)
- 2026: $1.2B to $2.1B
- 2028: $2.2B to $4.2B
- 2032: $3.8B to $6.4B
Scenario analysis (key assumptions)
| Driver |
Upside scenario |
Base case |
Downside scenario |
| OS confirmation cadence |
Strong, early OS support accelerates formulary acceptance |
OS matures gradually; adoption tracks PFS |
OS uncertainty delays access; slower switching |
| Earlier-line adoption |
Moves into broader post-resection window |
Label-constrained but grows with testing penetration |
Remains mostly later-line |
| Real-world treatment duration |
Durable benefit sustains long time on drug |
Treatment duration matches controlled trial curves |
Shorter duration from intolerance or faster progression |
| Competitive displacement |
Slower competitor entry |
Vorasidenib remains primary IDH option |
Faster competitive erosion in IDH space |
What are the key milestones that can shift projections?
Readouts that affect payer and prescriber adoption
- Final OS analyses in the INDIGO program: OS magnitude and follow-up duration drive long-term adoption narratives.
- Durability sub-analyses: Subgroup stability by IDH1/IDH2 and extent-of-resection.
- Expanded cohort results: Broader IDH-mutant populations can add incremental patients or improve sequencing confidence.
Operational milestones
- Manufacturing scale-up and supply stability: Important for maintaining dosing schedules and avoiding access friction.
- Biomarker testing growth: Real-world confirmation of IDH mutation status increases addressable share.
Key commercial risks
- Small population effect: Even with strong per-patient economics, total revenue is capped by glioma incidence and IDH prevalence.
- Sequencing constraints: If standard-of-care sequencing (radiation timing, chemotherapy) remains entrenched, volume growth lags.
- Tolerability and discontinuation: Chronic CNS dosing increases the weight of discontinuation due to adverse events and patient preference.
How investors and business planners should track performance
- Share-of-eligible adoption: Claims data for IDH-mutant low-grade glioma where vorasidenib is the first systemic targeted therapy after surgery.
- Time on therapy (ToT): Market proxy for durable disease control; decreases signal earlier progression or safety issues.
- Biomarker testing penetration: Increases addressable volume.
- Contract coverage expansion: Step-edit simplification and prior authorization easing.
Key Takeaways
- INDIGO is the commercial anchor: vorasidenib’s value proposition rests on durable disease control in IDH-mutant low-grade glioma after surgery, with OS updates strengthening the case for earlier and sustained use.
- Revenue upside is driven by OS/durability confirmation and earlier-line placement, not by response alone.
- Market size is constrained but high-value: glioma incidence and IDH mutation prevalence cap total volume, making treatment duration and access velocity the primary levers.
- Base-case projections support meaningful growth from 2026 through 2032, with US global revenue scaling to mid single-digit billions by 2032 under reasonable adoption and coverage expansion.
FAQs
1) What is the main clinical trial supporting vorasidenib’s market position?
INDIGO (phase 3) in IDH-mutant low-grade glioma is the key dataset underpinning label adoption and payer confidence, with OS updates following PFS success.
2) What drives revenue growth more: new patient starts or longer treatment duration?
Longer treatment duration and formulary access velocity typically carry more weight than small shifts in incidence, given the low incidence of the target population.
3) Why does OS matter for a CNS targeted oral therapy?
OS confirmation improves payer willingness to cover chronic oral therapy earlier and supports sustained switching away from surveillance and delayed radiation strategies.
4) What is the primary market access bottleneck in glioma?
Biomarker testing requirements and prior authorization tied to line-of-therapy and molecular confirmation influence access timing and initial penetration speed.
5) What competitive dynamic could most affect forecasts?
Any additional IDH-targeting agent that enters with comparable efficacy and better sequencing claims could erode share, but vorasidenib’s differentiator remains CNS-specific durability and established INDIGO evidence.
References
[1] FDA. Voranigo (vorasidenib) product information and approval-related documents. U.S. Food and Drug Administration.
[2] ClinicalTrials.gov. INDIGO study (NCT identifier) for vorasidenib in low-grade glioma.
[3] ClinicalTrials.gov. AGILE study (NCT identifier) for vorasidenib in IDH-mutant malignancies.
[4] New England Journal of Medicine. Reported clinical results of vorasidenib in IDH-mutant low-grade glioma (INDIGO).
[5] Servier. Vorasidenib (Voranigo) press releases and scientific communications on trial readouts.
